Haysaw, Unlike RD, ADHD should be much easier to partner. Pivotal ADHD trials are straightforward in design, and ADHD has much broader pharma interest than RD.
Once Cortex has the ADHD trial underway, the share price should start to reflect that reality.
Market Data 
Markets 
AI
